Postoperative Analgesic Effect of Subcostal TAPB for Laparoscopic Gastrectomy

Seoul National University

Status: Completed

Conditions: Postoperative Pain

Treatments: Drug: Ropivacaine 0.75% Injectable Solution; Device: 21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France); Procedure: Ultrasound guided subcostal transversus abdominis plane block (TAPB)

Study type: Interventional

Funder types: Other

Identifiers

NCT04138901

HS-2019-01

Details and patient eligibility

About

This prospective, randomized, single blinded study is designed to evaluate the postoperative analgesic efficacy of the ultrasound-guided subcostal transversus abdominis plane block in gastric cancer patients undergoing laparoscopic gastrectomy. We hypothesize that US guided subcostal TAP block with ropivacaine can significantly reduce postoperative opioid comparison in patients with laparoscopic gastrectomy.

Full description

Adult patients undergoing elective laparoscopic gastrectomy are randomly allocated to receive subcostal TAP block (n=56) or not (n=56), in addition to a standard postoperative analgesic regimen comprising of IV fentanyl-based patient-controlled analgesia (PCA) and NSAIDs as required. At the end of surgery, the TAP group patients will receive bilateral subcostal TAP block under ultrasound guidance with 15ml of 0.375% ropivacaine bilaterally. Each patient was assessed by a blinded investigator at 6, 12, 24, and 48 h postoperatively. The primary outcome is total fentanyl consumption at 24 h after surgery.

Enrollment: 112 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients scheduled to undergo elective laparoscopic gastrectomy under general anesthesia
• American Society of Anesthesiologists (ASA) physical classification I-III
• Consent to IV-patient controlled analgesia use
• Willingness and ability to sign an informed consent document

Exclusion criteria

• Do not understand our study
• Allergies to anesthetic or analgesic medications
• Wound infiltration analgesia for postoperative pain control
• Infection or anatomic abnormality at the needle insertion site
• Pregnancy/Breast feeder
• Medical or psychological disease that can affect the treatment response

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

112 participants in 2 patient groups

Group T

Experimental group

Description:

Patients receiving bilateral subcostal TAP block.

Treatment:

Procedure: Ultrasound guided subcostal transversus abdominis plane block (TAPB)

Drug: Ropivacaine 0.75% Injectable Solution

Device: 21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)

Group C

No Intervention group

Description:

Patients not receiving bilateral subcostal TAP block.